Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

2 Customer Reviews

  • Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

    Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NEHESWRHfW6ldHnvckBCe3OjeR?= MmnXNE4yNTNyIN88US=> MUG0PEBp MkfmbY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> Mln5NlY2OTNzN{K=
H460 M1H6SWZ2dmO2aX;uJGF{e2G7 MmLuNE4yNTNyIN88US=> MX:0PEBp NFf1c|lqdmS3Y3XzJGlESU1vMTDlfJBz\XO|aX;uJI9vKGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdA>? M3fnUFI3PTF|MUey
HKESC-2 M2TWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofxNlDDqM7:TR?= NFfVVXA1QMLiaNMg M2qwWpNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>? MXKyOlQ4PDZ7Mx?=
CaES-17 M3TQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrkN|YzOMLizszN NYniWpd1PDkEoHlCpC=> MnTkd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJGlEPTEEoI\hcJVmeyCxZjDvfIFtcXCuYYTpcuKh MUiyOlQ4PDZ7Mx?=
HKESC-2 NXL1R|ZRSXCxcITvd4l{KEG|c3H5 M124[|IxyqEQvF2= MYS0POKhcMLi MYfy[YR2[2W|IH;4ZYxqeGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz NEPlbFAzPjR5NE[5Ny=>
CaES-17 M3njdWFxd3C2b4Ppd{BCe3OjeR?= M2LTOlIxyqEQvF2= NFT1eo81QMLiaNMg NEP1ZYdz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ MmS3NlY1PzR4OUO=
A549 MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLDS3BSPS1zNkCg{txO MlfQOFjDqGkEoB?= MlzNSG1UVw>? MXPJR|UxRTF4Mz60JO69VQ>? MnXuNlY1PjR4NEO=
HCC827 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\SbG0xPS1zNkCg{txO MXm0POKhcMLi MUTEUXNQ M3LPU2lEPTB;NkmuNkDPxE1? NFzINnEzPjR4NE[0Ny=>
A549 M4[1dWFxd3C2b4Ppd{BCe3OjeR?= NYLJbGFDQDBiwsXN NGP2c5k1QMLiaNMg MXLEUXNQ MYjpcoR2[2W|IHHwc5B1d3Orcx?= NXHkT2tHOjZ2NkS2OFM>
HCC827 MnKyRZBweHSxc3nzJGF{e2G7 NGDFdno5OCEEtV2= NHjk[YU1QMLiaNMg MkPuSG1UVw>? MWnpcoR2[2W|IHHwc5B1d3Orcx?= NVzaZYFYOjZ2NkS2OFM>
SGC-7901/DDP NUD4VJB{TnWwY4Tpc44hSXO|YYm= NFPzb5kyOMLiwsXN NXrHN2lsOjRiaB?= MmD5bY5pcWKrdIOgZ5lkdG:xeInn[Y5ie2VvMjDhcoQhWC2pbInjc5Bzd3SnaX6g[ZhxemW|c3nvci=> NXK4cIt4OjZ2MEe2OVM>
SGC-7901  M2CxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOyOOKhcMLi NE\5ZnNKSzVyPUGxOU4xQCEQvF2= MoK3NlY1ODd4NUO=
SGC-7901/DDP M17wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorNNlTDqGkEoB?= NFTzRZlKSzVyPUO1MlQ2KM7:TR?= NWjnVoFlOjZ2MEe2OVM>
SGC-7901/DDP M2D3UmFxd3C2b4Ppd{BCe3OjeR?= NYHs[GJQOTEEoNM1US=> MX[yOEBp NHXsdJlqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIIfpeIgh[2m|cHzheIlv MmnkNlY1ODd4NUO=
SGC-7901/DDP M2XYSWZ2dmO2aX;uJGF{e2G7 MYSxNOKhyrWP NWLXSWRKOjRiaB?= MoPabY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gVE1odHmlb4Dyc5RmcW5idHjyc5VocCCkbH;jb4lv\yCHUEKsJIFv\CCrbnHjeIl3[XSrbnegVGtCKGGwZDDDVmVDyqB? NULlU4JROjZ2MEe2OVM>
SGC-7901/DDP NUXsW|lkTnWwY4Tpc44hSXO|YYm= NYXaSpk2OTEEoNM1US=> MYSyOEBp M1rUdYNifXOnczDhJI1iemunZDDk[YNz\WG|ZTDpckB1cGVibHX2[Ywhd2ZiQnPsMVIheHKxdHXpci=> NV3PN2Y1OjZ2MEe2OVM>
H357 NEC5OoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjYO{42NzFyIN88US=> MoHWOFghcA>? NHPKSIhFVVOR M4HRVIlvcGmkaYTzJINmdGxiZ4Lve5RpyqClb33ibY5m\CC5aYToJHNi[nW2b3PsZZg> NEjyZXQzPjByOUi3OC=>
TAF MX;GeY5kfGmxbjDBd5NigQ>? M1fjUFExyqEEtV2= MkjEO{Bl MX7h[oZm[3S|IGTBSpMh[WSqZYPpeoUheHKxcHXyeIlmew>? NHfzRZczPTl6N{GyOy=>
TAF NVr0dXZOTnWwY4Tpc44hSXO|YYm= MWKxNOKhyrWP NHW3dWQ{OC1zMkCgcYlv M{S0W5Bwd3KueTDh[oZm[3S|IHTBb5QheGixc4Doc5J6dGG2aX;uJINwdnOncYXlcpQhfG9iRVfGJJNq\26jbHnu[y=> MlnyNlU6QDdzMke=
TAF M2iz[2Z2dmO2aX;uJGF{e2G7 NX[ySJUzOTEEoNM1US=> MV60PEBp M1HwPIlv[3KnYYPld{BGT0[UIH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NUP4RlVEOjV7OEexNlc>
PANC-1 NXLtSHgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUeyNE83OC9zMECg{txO NX32WYlxOjRxNEivO|IhcA>? NG\XeZZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NUjOXoNlOjV7N{OwOlI>
PANC-1 MVrGeY5kfGmxbjDBd5NigQ>? NU\ZZ2w{OjBxNkCvNVAxKM7:TR?= MmjENlQhcA>? MV3heJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA> MYWyOVk4OzB4Mh?=
HeLa  Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK0NlDDqM7:TdMg NH;UW44zPMLiaB?= MXzlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? NYfESGN4OjV5N{C0NlM>
SACC-83 M2LN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPxNlDDqM7:TdMg M1rQTlI1yqCq M3fT[4VvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w M4HPc|I2PzdyNEKz
HeLa  NYfJZnN{SXCxcITvd4l{KEG|c3H5 M1fzfFIxyqEQvF5CpC=> NU[xSm4yOjUEoHi= M1XROoVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> M3nVUVI2PzdyNEKz
SACC-83 NYXzTpB5SXCxcITvd4l{KEG|c3H5 M2DS[FIxyqEQvF5CpC=> M{fieFI1yqCq M1zHXIVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> NV7XUJA1OjV5N{C0NlM>
HeLa  Mnu3SpVv[3Srb36gRZN{[Xl? MnnZNlAwPDBxOECg{txO MUWyOOKhcA>? M1[0fZVxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV M{fsclI2PzdyNEKz
SACC-83 MortSpVv[3Srb36gRZN{[Xl? M33KW|IxNzRyL{iwJO69VQ>? NW\uTIpqOjUEoHi= Ml\reZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q> M3nzNFI2PzdyNEKz
HLCZ01 MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvFb2ZMOOLCk{[wxsDDvU1? MknNOFghcA>? MVnEUXNQ M4XYVIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MofvNlU4OjR6OUm=
HLCZ01 NIPuSYxHfW6ldHnvckBCe3OjeR?= NYHlTHV1PDEEoN88US=> NGjKelczPCCq M4PycmROW09? M{PJUIlv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> NX33V3E4OjV5MkS4PVk>
HLCZ01 M4T0cGFxd3C2b4Ppd{BCe3OjeR?= M4f5e|QxyqEQvF2= NUPrOm1bOjRiaB?= MUTEUXNQ Mnzy[Y5p[W6lZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiSV\OMe6y M1zWdFI2PzJ2OEm5
HLCZ01 MnvuSpVv[3Srb36gRZN{[Xl? MlnuOFDDqM7:TR?= M3XnVVI1KGh? MWTEUXNQ Ml7TbY5kemWjc3XzJHRTSUmOIHX4dJJme3Orb36gZ49u[mmwZXSge4l1cCCLboTldoZmem:wLd8x NV;S[XVbOjV5MkS4PVk>
MGC803 NYnybWJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHGR4J7OC14MDFOwG0> MlLOO|IhcA>? Ml[5TWM2OD12Nz6yOgKBkcLz4pEJOk41OyEQvF2= M{njSFI2PzBzM{e4
SGC7901 NEe4NG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOwMVYxKM7:TR?= M2rJPVczKGh? NVzNe|FpUUN3ME20N{42O+LCidMx5qCKPS5zMjFOwG0> NEP4NYkzPTdyMUO3PC=>
MGC803 NUm1PINmTnWwY4Tpc44hSXO|YYm= NUT5XIFpPDEEoN88US=> MX24M|E3NzJ2IHi= M2L0bJVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> MofSNlU4ODF|N{i=
SGC7901 NEPETXBHfW6ldHnvckBCe3OjeR?= NFf1So81OMLizszN M{D6VVgwOTZxMkSgbC=> MnjVeZBz\We3bHH0d{BE[mxvYjDlfJBz\XO|aX;u MVyyOVcxOTN5OB?=
MCF-7  MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVuxM|ExKM7:TR?= NV3obnV7PzJiaB?= MnrNSG1UVw>? NVS4bJZ7\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= M{HSVFI2PjZ5NUGw
MDA-MB-231  MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL5NU8yOCEQvF2= Mki5O|IhcA>? NEjRcJZFVVOR MW\lcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>? M4KxelI2PjZ5NUGw
MDA-MB-231 MU\GeY5kfGmxbjDBd5NigQ>? MWWwMVQxKML3TR?= MYW0MVI1KGh? M2TNS4lv[3KnYYPld{BEV1hvMjDwdo91\WmwIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> Mn\mNlU2QDd|Mkm=
MCF-7 NUHPVm0{TnWwY4Tpc44hSXO|YYm= M120eVAuPDBiwsXN NUnpOW5EPC1{NDDo MV\lcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW|c3nvcuKh NXS4TZJ7OjV3OEezNlk>
MCF7-MX  M3q5cWZ2dmO2aX;uJGF{e2G7 M1WxRlAuPDBiwsXN NXXZZmVbPC1{NDDo MojG[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? MYiyOVU5PzN{OR?=
MDA-MB-231 M3PFPGZ2dmO2aX;uJGF{e2G7 NEPwRpMxNTRyINM1US=> NX7nRYF6PC1{NDDo M2C3WZN1cW23bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhSUKFR{KgeZAhfG9iND6yO{B1cW2nczD0c{Bkd262cn;sJIxmfmWuIHL5JFEzKGkEoB?= Mn[yNlU2QDd|Mkm=
A2780 MmfCSpVv[3Srb36gRZN{[Xl? MX21M|ExNzF3IN88US=> NVvxV5d7PDhiaB?= NXz6XHBx\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnvHNlU1OjR6OUi=
SKOV3  NEP2RVhHfW6ldHnvckBCe3OjeR?= NI[1fmQ2NzFyL{G1JO69VQ>? M{\JdlQ5KGh? NWDuRZlo\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MkOwNlU1OjR6OUi=
A2780 MVLGeY5kfGmxbjDBd5NigQ>? NIfkcmU2NzFyL{G1JO69VQ>? NIe5Rlc1QCCq M{T3e4Vt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5? Mo\ONlU1OjR6OUi=
SKOV3  Mn7YSpVv[3Srb36gRZN{[Xl? MoizOU8yOC9zNTFOwG0> NXftTWlMPDhiaB?= NX6wOlZv\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= MVWyOVQzPDh7OB?=
A2780 MoLCSpVv[3Srb36gRZN{[Xl? Mnf0OU8yOC9zNTFOwG0> MkTBOFghcA>? M1TnZYRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?= NVXPVHhnOjV2MkS4PVg>
SKOV3  MofESpVv[3Srb36gRZN{[Xl? Mn21OU8yOC9zNTFOwG0> MVS0PEBp NVmweo5p\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu MmfoNlU1OjR6OUi=
A2780 MmfSSpVv[3Srb36gRZN{[Xl? MVy1M|ExNzF3IN88US=> NEnXRlQyKGh? M1fue4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M33DcFI2PDJ2OEm4
SKOV3  M1;uPGZ2dmO2aX;uJGF{e2G7 NHfOcpQ2NzFyL{G1JO69VQ>? MV[xJIg> M2jSRYlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M4\oRVI2PDJ2OEm4
HCT-15 NV3LWmlETnWwY4Tpc44hSXO|YYm= M1rT[|ExNTVyIN88US=> MmO5Ok0{PiCq MnnsbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= NWL3WlB1OjV{MUiwNlg>
HT-29  NIXobYJHfW6ldHnvckBCe3OjeR?= MYSxNE02OCEQvF2= Mn7TOk0{PiCq MmK4bY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= M4LkU|I2OjF6MEK4
HSC3  MnTFR4VtdCCYaXHibYxqfHliQYPzZZk> NHXtdoMx6oDVNECg{txO MoSzOFghcA>? M{Ts[GlEPTB;MkWuOeKyOS55OECg{txO Mkf3NlUyQTh5OEm=
HSC3  M2jCWGFxd3C2b4Ppd{BCe3OjeR?= MVyyOUDPxE1? NEHCbWU1QCCq MUTpcoR2[2W|IHHwc5B1d3Orcx?= MoH3NlUyQTh5OEm=
HSC3  NVPrXZY2TnWwY4Tpc44hSXO|YYm= M4TaNVI2KM7:TR?= M2HocVQ5KGh? MmTK[ZhpcWKrdIOgd4lodmmoaXPhcpRtgSC{ZXT1Z4VlKG2rZ4LheIlwdiClb33ibY5m\CC5aYToJGNGXA>? MVOyOVE6QDd6OR?=
HSC3  Mm[0SpVv[3Srb36gRZN{[Xl? NXPUW3pGOjVizszN NGmwO281QCCq MXXpcohq[mm2czDIV2M{KGOnbHygbY53[XOrb36gZ49u[mmwZXSge4l1cCCFRWS= NFSwZXMzPTF7OEe4PS=>
HSC3  NWCxfmFDTnWwY4Tpc44hSXO|YYm= NEHheGEzPSEQvF2= Ml;PO|IhcA>? MmXa[IVkemWjc3XzJG1OWC1{IHHu[EBOVVBvOTDwdo91\Wmwc9Mg NGXN[|MzPTF7OEe4PS=>
201T  MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHRO|IhcA>? MljlSG1UVw>? NXT2cVJSUUN3ME20PE43KML3TR?= MVOyOVA2Pzl2MR?=
273T NH;UOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlGyO|IhcA>? Mn7QSG1UVw>? NV[z[lRJUUN3ME24NE42KML3TR?= MYqyOVA2Pzl2MR?=
Hep-2 NGH0dIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\XUVMxNzVyL{GwNEDPxE1? M3rwOlEzNzJ2L{O2M|Q5KGh? NYHaRZB{TE2VTx?= NHTH[Y5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MVmyOFk6QDV4NB?=
Hep-2 NYi2T5Z2SXCxcITvd4l{KEG|c3H5 NIWwWGY2OCEQvF2= NX\2U4E1OC12ODDo MXrEUXNQ MoPrbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MkXlNlQ6QTh3NkS=
Hep-2 MluySpVv[3Srb36gRZN{[Xl? MonaOVAh|ryP NWLjRYJFOC12ODDo M1TGcmROW09? M3;ENJJm\HWlZYOgeIhmKHSnbH;t[ZJie2ViYXP0bZZqfHliZ4Lh[JVidGy7 M{\DUFI1QTl6NU[0
Hep-2 MUfGeY5kfGmxbjDBd5NigQ>? NIWydG82OCEQvF2= M{e0XVAuPDhiaB?= NFPLOoFFVVOR NXHTSXRu\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gbHRGWlR? MX[yOFk6QDV4NB?=
SGC-7901 NWLVPW9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWKxNE82OC9zMECg{txO NHTCelMzPC92OD:3NkBp MVfEUXNQ MmHPbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NEPtOoMzPDl7Mkm1PC=>
MKN-45 M4nCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3XUpEyOC93MD:xNFAh|ryP M1\VXFI1NzR6L{eyJIg> M3nlVmROW09? M4OxcolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NIrONWszPDl7Mkm1PC=>
SGC-7901 Mn3HSpVv[3Srb36gRZN{[Xl? M4rlW|ExNzVyL{GwNEDPxE1? MUe0PEBp MV7EUXNQ MlXB[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Mk\pNlQ6QTJ7NUi=
MKN-45 NEjjTXNHfW6ldHnvckBCe3OjeR?= NUHwO|BOOTBxNUCvNVAxKM7:TR?= NF\MeII1QCCq NGLy[JJFVVOR Mlrl[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MW[yOFk6Ojl3OB?=
C666-1 MorpR5l1d3SxeHnjbZR6KEG|c3H5 M3Tl[|IxNThyIN88US=> NGX2XXkzPCCq M{m0TIRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> M1Gz[FI1QDV2OEO4
CNE-1 NX;ydZZGS3m2b4TvfIlkcXS7IFHzd4F6 M3P0SVIxNThyIN88US=> M1S1fVI1KGh? NF;zXHhl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh MX:yOFg2PDh|OB?=
CNE-2 MmnVR5l1d3SxeHnjbZR6KEG|c3H5 Mo\SNlAuQDBizszN NVL0[lF2OjRiaB?= NV63SHp1\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? NWTkUYxDOjR6NUS4N|g>
C666-1 NFT5UmhEgXSxdH;4bYNqfHliQYPzZZk> NHHiToo3OCEQvF2= MVq3JIQ> MXTlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?= M2Lh[FI1QDV2OEO4
CNE-1 NGXPeFJEgXSxdH;4bYNqfHliQYPzZZk> NVTvTlUzPjBizszN MVy3JIQ> NGHaSIdmdmijbnPld{Bz[WSrYYTpc44h[3m2b4TvfIlkcXS7IITodo92\2hiQ1;YMVIu\GWyZX7k[Y51KG2jbn7ldi=> MnLiNlQ5PTR6M{i=
SNU-1041 NEjBZ4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;2S20xNTRyIN88US=> NYXMcIl1PDhiaB?= Mm\GbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M365T|I1Pjl{N{Cz
SNU-1041 MV3GeY5kfGmxbjDBd5NigQ>? MlzwNlAwOzBizszN NWHjW5ZuPCCq NIXPWVJqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>? MYeyOFY6OjdyMx?=
SNU-1041 NWXnZ4FRTnWwY4Tpc44hSXO|YYm= M{\TRlAuPDBizszN MVS0JIg> NF\lU212eC2{ZXf1cIF1\XNiQ1jPVOKh[W[2ZYKgeJJm[XSvZX70JJdqfGhiaHnnbEBkd26lZX70doF1cW:wcx?= M4HhZ|I1Pjl{N{Cz
SGC-7901 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWq1NE0yOjVizszN NWP1[o9ZOjRxNEivO|IhcA>? M2X0RYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M1TLZlI1Pjd4M{m0
SGC-7901 MkjiRZBweHSxc3nzJGF{e2G7 MmHnNVAxKM7:TR?= NYDSV4pyPzJiaB?= MVzpcoR2[2W|IHHwc5B1d3Orcx?= M2PvR|I1Pjd4M{m0
SGC-7901 MXfGeY5kfGmxbjDBd5NigQ>? M3X2V|c2NzFyMD:xNlUh|ryP Ml7aNlQwPDhxN{KgbC=> MniwbY5kemWjc3XzJINie3Cjc3WtPEBidmRiLUmgcXJPSSCneIDy[ZN{cW:wIHnuJIJwfGhidHnt[UBidmRiZH;z[UBu[W6wZYK= NXnDWoJKOjR4N{[zPVQ>
LMeC  NYfic|B5TnWwY4Tpc44hSXO|YYm= M33YRVIxNzVyIN88US=> NVjweJgyPDhiaB?= MnfS[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IIDyc5RmcW5? NULTS4pHOjR4NU[3OFY>
CMeC-1 M3LMS2NmdGxiVnnhZoltcXS7IFHzd4F6 NX7lTFV4OjBxNUCg{txO M3fMZlQ5KGh? MXnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MVGyOFY2Pjd2Nh?=
LMeC MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIrz[I8zOC93MDFOwG0> NWDOTHk5PDhiaB?= M4r4R4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MmTUNlQ3PTZ5NE[=
CMeC-1 NFTkNFhHfW6ldHnvckBCe3OjeR?= NWLxdY9oOjBxNUCg{txO NXPzRppYPDhiaB?= NHHnZ5ZqdmS3Y3XzJGcyNVNiYYLy[ZN1 MX[yOFY2Pjd2Nh?=
LMeC NWXTZpJRTnWwY4Tpc44hSXO|YYm= NUnlXJU5OjBxNUCg{txO M4n5XlQ5KGh? NYP0XphrcW6mdXPld{BIOS2VIHHydoV{fA>? MnnnNlQ3PTZ5NE[=
CMeC-1 MlH2SpVv[3Srb36gRZN{[Xl? MmHvNlAwPTBizszN NX3OOVdoPDhiaB?= NUjh[WRm\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NIXybIwzPDZ3Nke0Oi=>
LMeC MkLXSpVv[3Srb36gRZN{[Xl? NIjFeY4zOC93MDFOwG0> M{jlSFQ5KGh? NXf4NpRp\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4ToWVI1PjV4N{S2
CMeC-1 NHPydY5HfW6ldHnvckBCe3OjeR?= NV3JSmV7OjBxNUCg{txO M1;Jc|Q5KGh? MWTpcoR2[2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u MlnmNlQ3PTZ5NE[=
LMeC NEDqSpdHfW6ldHnvckBCe3OjeR?= NUDRVXRjOjBxNUCg{txO MXu0PEBp MoDwbY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> MVyyOFY2Pjd2Nh?=
OVCAR-3 MmO3R4VtdCCYaXHibYxqfHliQYPzZZk> NXzwc2pCOTBiwsXN MV2xJIg> NHrGRnpmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh NYTBeYdxOjR3MkCyNlc>
OVCAR-3 NYTuOGFESXCxcITvd4l{KEG|c3H5 MXSxNEDDvU1? MYGxJIg> Mnm0dJJwdW:2ZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIFxd3C2b4Ppd:Kh MYiyOFUzODJ{Nx?=
OVCAR-3 M4e1ZmZ2dmO2aX;uJGF{e2G7 NHm3XYIyOCEEtV2= NHK2NG8yKGh? NXK1SWdm\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZT25xsA> M2XkNFI1PTJyMkK3
OVCAR-3 MX7GeY5kfGmxbjDBd5NigQ>? NY\aZ21zOTBiwsXN MUWxJIg> MWDkc5dvNXKnZ4XsZZRmeyCQRj5OvmIh[WO2aY\heIlwdiCrbnT1Z4VlKGK7IIDhZ4xqfGG6ZXy= NHrlTFMzPDV{MEKyOy=>
OVCAR-3 M1y4OWZ2dmO2aX;uJGF{e2G7 NVznclR{OTBiwsXN NUXMfVI{OSCq MWjpcohq[mm2czDwZYNtcXSjeHXsMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> MlvCNlQ2OjB{Mke=
CF33 NFzPO5NHfW6ldHnvckBCe3OjeR?= NHm5fFEyODBizszN MXKyOEBp MWLpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIFPPXE0zKHC{b4TlbY4h\XiycnXzd4lwdg>? MVOyOFUxOzd6Mh?=
CF33 M3j2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnJ[WRnOTBvMUCwJO69VQ>? NWfpNZFLOC12IHS= NEnSWJRqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mo\qNlQ2ODN5OEK=
CF33 NVP4VZVXTnWwY4Tpc44hSXO|YYm= NYH2ZVNEOTBvMUCwJO69VQ>? NYnsfIl4PC1{NDDo Ml6z[IVkemWjc3XzJINmdGy|IHnuJJRp\SCVIIDoZZNmKGGwZDDpcoNz\WG|ZYOgZ4VtdHNiaX6gS|AwTzFiYYLy[ZN1 MUGyOFUxOzd6Mh?=
LNCaP MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\HdVIwPS9zMDFOwG0> MUK5OkBp MmPibY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?= MojONlQzQTZ7N{i=
LNCaP MVzBdI9xfG:|aYOgRZN{[Xl? M1LjWFIwPS9zMDFOwG0> MUC5OkBp M3TLcolv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiYYTvdpZie3SjdHnu M2nuWlI1Ojl4OUe4
PC-3  MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOwMVUxKM7:TR?= NHTjPGo1QOLCiXi= NHfBepdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MmDkNlQyOjd6OEK=
PC-3  MYjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2jjbFAuOTByIN88US=> M3HjUFczKGh? NXLLWYRq\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NIrzV|czPDF{N{i4Ni=>

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT02845336 Recruiting Thyroid Eye Disease Johns Hopkins University January 31, 2017 Phase 2
NCT02054104 Suspended Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 27, 2014 Phase 1|Phase 2
NCT01143545 Completed Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 26, 2010 Phase 1
NCT01313429 Completed Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancies National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 23, 2011 Phase 1
NCT02160301 Suspended Post Operative Pain Control University of North Carolina, Chapel Hill November 2017 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID